Vogenx Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | VOGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVOGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −299.0x | −3.6x | −0.4x | |
PEG Ratio | - | −0.26 | 0.00 | |
Price / Book | −334.1x | −7.8x | 2.6x | |
Price / LTM Sales | - | 2.6x | 3.0x | |
Upside (Analyst Target) | 69.2% | 90.8% | 55.0% | |
Fair Value Upside | Unlock | 8.3% | 7.6% | Unlock |
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.